Resmed Inc. (RMD) stock forecast and price target
Price $239.53 · data as of November 13, 2026
12-month price target
Gold marker: average target · white marker: today’s price ($239.53)
Analyst ratings
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends June 30, 2027 | $12.14 | +8.7% | $5.8B |
| Next fiscal year ends June 30, 2028 | $13.23 | +8.9% | $6.2B |
| Next quarter ends December 31, 2026 | $2.99 | +6.4% | $1.5B |
| Quarter after ends March 31, 2027 | $3.06 | +6.9% | $1.5B |
Consensus of the analysts covering Resmed, updated daily. In the last 30 days 15 estimates were raised and 4 lowered.
Our model vs. Wall Street
Analysts see 10.4% upside over 12 months. Our discounted cash flow model with moderate assumptions puts Resmed’s intrinsic value about 28% below today’s market value, and it scores 4.2 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.
Frequently asked questions
What is the Resmed stock price target?
The average 12-month target from 17 analysts is $264.33, 10.4% above the current price of $239.53 Targets range from $210.00 to $320.00.
Is Resmed a buy according to analysts?
The consensus rating is “Buy” (2 strong buy, 7 buy, 10 hold, 1 sell). Ratings are opinions, not guarantees; this is not investment advice.
How much is Resmed expected to earn?
Analysts expect EPS of $12.14 for the fiscal year ending June 30, 2027 and $13.23 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.